NasdaqGS:KRYSBiotechs
Assessing Krystal Biotech (KRYS) Valuation After KB707 RMAT Designation Boosts Oncology Pipeline Prospects
Krystal Biotech (KRYS) is back in focus after the FDA granted Regenerative Medicine Advanced Therapy designation to KB707, an inhaled immunotherapy candidate for advanced or metastatic non small cell lung cancer.
See our latest analysis for Krystal Biotech.
Krystal Biotech’s latest KB707 RMAT news arrives while the stock trades at US$276.45, with a 34.09% 90 day share price return and an 80.40% 1 year total shareholder return. This suggests momentum has been building over both shorter and...